ACADIA Pharmaceuticals Announces Appointment of Austin D. Kim as Executive Vice President, General Counsel and Secretary

SAN DIEGO—(BUSINESS WIRE)—Jul. 19, 2018—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesto address unmet medical needs in central nervous system (CNS)disorders, today announced that Austin D. Kim has joined ACADIA asExecutive Vice President, General Counsel and Secretary. He will reportto Steve Davis, ACADIA’s President and Chief Executive Officer and serveas a member of the company’s Executive Management Committee.

This press release features multimedia. View the full release here:https://www.businesswire.com/news/home/20180719005819/en/

Austin D. Kim, Executive Vice President, General Counsel and Secretary (Photo: Business Wire)

The company previously announced in February that Glenn F. Baity, whoserved as Executive Vice President, General Counsel and Secretary since2004, would be retiring. Mr. Baity will remain with ACADIA throughcompletion of a transition period.

“We are delighted to have Austin join the ACADIA team,” said Mr. Davis.“Austin has a proven record leading corporate legal and governanceactivities for global biopharmaceutical companies. His expertise andleadership track record will be greatly valued as we continue to advanceNUPLAZID^® and explore new opportunities for recognizing thepromise of our CNS portfolio and delivering shareholder value.”

From 2006 until 2017, Mr. Kim held several senior legal positions atTeva Pharmaceuticals, a global specialty pharmaceutical company. AtTeva, Mr. Kim was most recently Vice President and Deputy GeneralCounsel, Corporate/M&A, handling corporate and securities law matters,acquisitions and corporate development, capital markets transactions andcorporate governance matters. Before joining Teva, Mr. Kim was DeputyGeneral Counsel at IVAX Corporation, a global generic pharmaceuticalcompany, which was acquired by Teva in 2006. Earlier in his career, Mr.Kim was a senior lawyer at Transamerica Corporation, practiced law atPillsbury, Madison & Sutro and clerked for Judge Vaughn Walker of theUnited States District Court, Northern District of California. Mr. Kimreceived his J.D. degree from Columbia University School of Law and hisA.B. in English Literature and Economics from Stanford University.

Mr. Davis added: “I would also like to express my appreciation to Glennfor his leadership during his many years with ACADIA, beginning when thecompany first went public in 2004. His guidance during these formativeyears for ACADIA has contributed significantly to the success we havehad as a company and the tremendous value we have provided to patientsaffected by CNS disorders.”

About ACADIA Pharmaceuticals
ACADIA is a biopharmaceuticalcompany focused on the development and commercialization of innovativemedicines to address unmet medical needs in central nervous systemdisorders. ACADIA has developed and is commercializing the first andonly medicine approved for the treatment of hallucinations and delusionsassociated with Parkinson’s disease psychosis. In addition, ACADIA hasongoing clinical development efforts in additional areas withsignificant unmet need including dementia-related psychosis,schizophrenia inadequate response, schizophrenia-negative symptoms andmajor depressive disorder. This press release and further informationabout ACADIA can be found at: www.acadia-pharm.com.

About NUPLAZID^® (pimavanserin)
NUPLAZIDis the first FDA-approved treatment for hallucinations and delusionsassociated with Parkinson’s disease psychosis. NUPLAZID is anon-dopaminergic, selective serotonin inverse agonist preferentiallytargeting 5-HT_2A receptors that are thought to play animportant role in Parkinson’s disease psychosis. NUPLAZID is an oralmedicine taken once a day with a recommended dose of 34 mg. ACADIAdiscovered and developed this new chemical entity and holds worldwiderights to develop and commercialize NUPLAZID.

Forward-Looking Statements
Statements in this press releasethat are not strictly historical in nature are forward-lookingstatements. These statements include but are not limited to statementsrelated to advancing NUPLAZID; exploring new opportunities forrecognizing the promise of ACADIA’s CNS portfolio; and deliveringshareholder value. These statements are only predictions based oncurrent information and expectations and involve a number of risks anduncertainties. Actual events or results may differ materially from thoseprojected in any of such statements due to various factors, includingthe risks and uncertainties inherent in drug discovery, development,approval and commercialization, and the fact that past results ofclinical trials may not be indicative of future trial results. For adiscussion of these and other factors, please refer to ACADIA’s annualreport on Form 10-K for the year ended December 31, 2017 as well asACADIA’s subsequent filings with the Securities and Exchange Commission.You are cautioned not to place undue reliance on these forward-lookingstatements, which speak only as of the date hereof. This caution is madeunder the safe harbor provisions of the Private Securities LitigationReform Act of 1995. All forward-looking statements are qualified intheir entirety by this cautionary statement and ACADIA undertakes noobligation to revise or update this press release to reflect events orcircumstances after the date hereof, except as required by law.

Important Safety Information and Indication forNUPLAZID (pimavanserin)

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITHDEMENTIA-RELATED PSYCHOSIS
Elderly patients withdementia-related psychosis treated with antipsychotic drugs are at anincreased risk of death. NUPLAZID is not approved for the treatment ofpatients with dementia-related psychosis unrelated to the hallucinationsand delusions associated with Parkinson’s disease psychosis.

NUPLAZID is an atypical antipsychotic indicated for the treatment ofhallucinations and delusions associated with Parkinson’s diseasepsychosis.

Contraindication: NUPLAZID is contraindicated in patients with a historyof a hypersensitivity reaction to pimavanserin or any of its components.Rash, urticaria, and reactions consistent with angioedema (e.g., tongueswelling, circumoral edema, throat tightness, and dyspnea) have beenreported.

QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use ofNUPLAZID should be avoided in patients with known QT prolongation or incombination with other drugs known to prolong QT interval includingClass 1A antiarrhythmics or Class 3 antiarrhythmics, certainantipsychotic medications, and certain antibiotics. NUPLAZID should alsobe avoided in patients with a history of cardiac arrhythmias, as well asother circumstances that may increase the risk of the occurrence oftorsade de pointes and/or sudden death, including symptomaticbradycardia, hypokalemia or hypomagnesemia, and presence of congenitalprolongation of the QT interval.

Adverse Reactions: The most common adverse reactions (≥2% for NUPLAZIDand greater than placebo) were peripheral edema (7% vs 2%), nausea (7%vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%),constipation (4% vs 3%), and gait disturbance (2% vs <1%).

Drug Interactions: Coadministration with strong CYP3A4 inhibitors (e.g.,ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mgtaken orally as one tablet once daily. Coadministration with strongCYP3A4 inducers may reduce NUPLAZID exposure. Monitor patients forreduced efficacy and an increase in NUPLAZID dosage may be needed.

Pediatric Use: Safety and efficacy have not been established inpediatric patients.

Dosage and Administration: Recommended dose: 34 mg taken orally oncedaily, without titration.

NUPLAZID is available as 34 mg capsules, 17 mg tablets and 10 mg tablets.

For additional Important Safety Information, including Boxed WARNING,please see the full Prescribing Information for NUPLAZID at https://www.nuplazid.com/pdf/NUPLAZID_Prescribing_Information.pdf.

Source: ACADIA Pharmaceuticals Inc.

Investor Contact:

ACADIA Pharmaceuticals Inc.
ElenaRidloff, CFA
(858) 558-2871
ir@acadia-pharm.com
or
MediaContact:
Taft Communications
Bob Laverty
(609)558-5570
bob@taftcommunications.com